Davunetide (NAP/AL-108) vs P21 (CNTF-Derived Peptide)
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Davunetide (NAP/AL-108) or P21 (CNTF-Derived Peptide)?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Davunetide (NAP/AL-108) and P21 (CNTF-Derived Peptide)?
Davunetide targets microtubule stabilization for tauopathy; P21 targets neurogenesis via cell cycle modulation - different mechanisms addressing different aspects of neurodegeneration.
Evidence Comparison
Davunetide: Phase 2/3 human trial data in PSP (failed, Boxer 2014). P21 peptide: CDKN1A fragment, rodent neurogenesis only. Davunetide has substantially more translational data despite its negative clinical outcome.
Evidence Context Favoring Davunetide (NAP/AL-108)
Tauopathy or microtubule-stabilization research with access to human PK and safety data from the failed trial.
Evidence Context Favoring P21 (CNTF-Derived Peptide)
Neurogenesis-focused preclinical research where CDKN1A-pathway cell cycle modulation is the mechanism of interest.
Side-by-Side Snapshot
| Evidence grade | Davunetide (NAP/AL-108): Level C P21 (CNTF-Derived Peptide): Level D |
|---|---|
| Research status | Davunetide (NAP/AL-108): Phase 2 P21 (CNTF-Derived Peptide): Preclinical |
| Primary category | Davunetide (NAP/AL-108): Cognitive & Nootropic P21 (CNTF-Derived Peptide): Cognitive & Nootropic |
| Cited studies | Davunetide (NAP/AL-108): 3 P21 (CNTF-Derived Peptide): 2 |